Could A Netflix-Like Subscription Service Be The Answer To Curbing High Drug Prices?

Information retailers report on tales associated to pharmaceutical pricing.

A Netflix Model For Hepatitis C: One Price, Unlimited Meds

Two states combating an escalating hepatitis C disaster will quickly pay a flat payment for limitless medication — Netflix model — to deal with prisoners and low-income residents affected by the lethal liver illness, with the objective of all however eliminating the an infection. Netflix, the favored DVD and video streaming service, prices prospects a month-to-month payment that entitles them to view all the films they need. Louisiana and Washington state wish to do one thing comparable with the costly medicines that present a remedy for hepatitis C. (Ollove, 2/25)

Nonprofit Trying To Upend Drug Costs Will Work With Pharma, Not Against It 

A nonprofit based to handle a urgent U.S. health-care downside by manufacturing much-needed medication which have fallen into brief provide, or which are too costly, will begin out with a unique strategy: shopping for the medication from pharmaceutical corporations. Civica Rx was launched amid fanfare final 12 months, backed by philanthropic donors and lots of of hospitals. Fed up with shortages or skyrocketing costs for merchandise like saline answer and epinephrine, Civica stated in September that it deliberate to “straight manufacture generic medication or sub-contract manufacturing to respected contract manufacturing organizations.” (Koons, 2/20)

$375,000 Price Leads Disabled Mom To Ration Meds

Bhanu Patel could not consider the information. The price of the treatment that permits her to maneuver — the one which enabled her to stroll stairs once more — shot as much as $375,000. Concern gripped her: What would this imply for her independence? Would she turn out to be a monetary burden on her household? How is that this attainable within the nation that is given her a lot? The previous three years, she stated, the treatment had been utterly free as a part of a specialty program. Till lately, the drug was referred to as 3,4-DAP made by Jacobus Pharmaceutical. However late final 12 months, Catalyst Prescription drugs received FDA approval for a barely modified model of the drug after two small medical trials and introduced an annual listing value of $375,000 for the brand new drug, known as Firdapse. (Drash, 2/20)

Two Drugs For Spinal Muscular Atrophy Should Be Priced How Low?

Two medicines designed to deal with spinal muscular atrophy, a uncommon and sometimes deadly genetic illness affecting muscle energy and motion, must carry a lot lower cost tags than the producers desire to be able to be thought of value efficient, based on an up to date evaluation. And the estimates are more likely to intensify ongoing debate over the price of new therapies, particularly for extremely choose affected person populations. One is a forthcoming gene remedy from Novartis (NVS) that the corporate has indicated could also be priced at $Four million to $5 million. (Silverman, 2/22)

Sanofi, Regeneron Lose U.S. Patent Challenge To Amgen Cholesterol Drug

Biotech firm Amgen Inc stated on Monday a U.S. jury confirmed the validity of patents on its ldl cholesterol drug Repatha, rejecting a problem by Regeneron Prescription drugs Inc and Sanofi SA. Sanofi and Regeneron had stipulated that if the 2 Amgen patents have been legitimate, their collectively developed ldl cholesterol drug Praluent infringed them. Amgen Chief Government Robert Bradway stated in a press release that the corporate was “grateful that the jury weighed the proof rigorously and acknowledged the validity of Amgen’s patents.” (2/25)

The Wall Street Journal:
Blackstone Life Sciences And Novartis To Launch Cardiovascular Drug Company

Blackstone Group LP is partnering with Novartis AG to develop medication to deal with blood clots, the primary funding by the private-equity agency’s new life-sciences enterprise. The 2 corporations plan to announce Wednesday that they may type a brand new firm known as Anthos Therapeutics. Blackstone Life Sciences is contributing $250 million to the enterprise and can management the corporate. Anthos will use a Novartis antibody that targets two clotting components. Novartis may have a minority stake in Anthos. (Gottfried, 2/26)

Did ‘Opportunism’ Prompt Bigger Price Hikes Following Competition? 

After three broadly used rheumatoid medicines started dealing with new competitors a decade in the past, annual remedy prices for the older medication rose quicker than if the rival medicines had not been launched, based on a brand new evaluation, which prompt “opportunism” by producers brought on sufferers and taxpayers to shoulder larger bills. Right here’s the background: Previous to 2009, simply three so-called TNF inhibitors —Remicade, Humira, and Enbrel — have been used to deal with varied inflammatory maladies, however the aggressive panorama started altering that 12 months when two extra medicines have been launched — Simponi and Cimzia. By 2013, an intravenous model of Simponi additionally turned accessible. (Silverman, 2/20)

Ipsen To Buy Clementia Pharmaceuticals In Deal Worth Up To $1.3 Billion

rench healthcare firm Ipsen has agreed to purchase U.S. peer Clementia Prescription drugs in a deal value as much as $1.31 billion, the businesses stated on Monday, serving to to spice up Ipsen’s portfolio of merchandise treating uncommon ailments. Ipsen’s shares dipped 0.6 p.c after the corporate stated the takeover would initially weigh on margins as a result of prices of forthcoming trials for Clementia merchandise, however it hoped they might recuperate in a while. (2/25)

The Associated Press:
Bipartisan Bill Targets Prescription Drug Costs In Wisconsin

A bipartisan proposal within the Wisconsin Legislature makes an attempt to decrease prescription drug prices and supply extra data to shoppers concerning the true value of their treatment. The invoice unveiled Tuesday targets middlemen known as pharmacy profit managers. They discount drug costs on behalf of insurers and employers, handle plans and course of claims. (Bauer, 2/26)

Former Novartis Exec Wins $1.5 Million After Claim Of Retaliation 

A former Novartis (NVS) worker was awarded practically $1.5 million in damages over claims that she was fired in retaliation for complaining {that a} proposed drug research gave the impression to be a kickback, though the jury agreed that she violated an organization coverage. Min Amy Guo, who had been govt director of the Well being Economics and Outcomes Analysis Group, objected to a research that may have examined unapproved, or off-label, makes use of of the Affinitor breast most cancers remedy, based on the lawsuit she filed in a New Jersey state court docket in 2014. (Silverman, 2/26)

That is a part of the KHN Morning Briefing, a abstract of well being coverage protection from main information organizations. Join an email subscription.

le = window.adsbygoogle || []).push({});

free web hosting site

Leave a Reply

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker